DE60005471D1 - EP4 Rezeptor selektive Agonisten zur Behandlung der Osteoporose - Google Patents
EP4 Rezeptor selektive Agonisten zur Behandlung der OsteoporoseInfo
- Publication number
- DE60005471D1 DE60005471D1 DE60005471T DE60005471T DE60005471D1 DE 60005471 D1 DE60005471 D1 DE 60005471D1 DE 60005471 T DE60005471 T DE 60005471T DE 60005471 T DE60005471 T DE 60005471T DE 60005471 D1 DE60005471 D1 DE 60005471D1
- Authority
- DE
- Germany
- Prior art keywords
- osteoporosis
- treatment
- selective agonists
- receptor selective
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17135399P | 1999-12-22 | 1999-12-22 | |
US171353P | 1999-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60005471D1 true DE60005471D1 (de) | 2003-10-30 |
DE60005471T2 DE60005471T2 (de) | 2004-04-22 |
Family
ID=22623430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60005471T Expired - Fee Related DE60005471T2 (de) | 1999-12-22 | 2000-12-11 | EP4 Rezeptor selektive Agonisten zur Behandlung der Osteoporose |
Country Status (36)
Country | Link |
---|---|
US (2) | US6737437B2 (de) |
EP (1) | EP1110949B1 (de) |
JP (1) | JP2001181210A (de) |
KR (1) | KR100419681B1 (de) |
CN (1) | CN1413190A (de) |
AP (2) | AP2001002357A0 (de) |
AT (1) | ATE250575T1 (de) |
AU (2) | AU1293101A (de) |
BG (1) | BG106882A (de) |
BR (1) | BR0016560A (de) |
CA (1) | CA2329678A1 (de) |
CO (1) | CO5251453A1 (de) |
CR (1) | CR6678A (de) |
CZ (1) | CZ20022048A3 (de) |
DE (1) | DE60005471T2 (de) |
DK (1) | DK1110949T3 (de) |
EA (1) | EA005293B1 (de) |
EE (1) | EE200200355A (de) |
ES (1) | ES2204458T3 (de) |
GE (1) | GEP20043203B (de) |
HR (1) | HRP20020537A2 (de) |
HU (1) | HUP0005001A3 (de) |
IL (1) | IL140325A0 (de) |
IS (1) | IS6388A (de) |
MA (1) | MA26852A1 (de) |
MX (1) | MXPA02006322A (de) |
NO (1) | NO20022925D0 (de) |
OA (1) | OA12117A (de) |
PE (1) | PE20010953A1 (de) |
PL (1) | PL356662A1 (de) |
PT (1) | PT1110949E (de) |
SK (1) | SK8552002A3 (de) |
TR (2) | TR200201643T2 (de) |
UA (1) | UA72293C2 (de) |
WO (1) | WO2001046140A1 (de) |
ZA (1) | ZA200007694B (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
CZ20031257A3 (cs) * | 2000-11-27 | 2004-04-14 | Pfizer Products Inc. | Selektivní agonisty receptoru EP4 při léčení osteoporosy |
CN100371322C (zh) | 2001-07-16 | 2008-02-27 | 霍夫曼-拉罗奇有限公司 | 作为***素类化合物激动剂的2-吡咯烷酮衍生物 |
JP2004521954A (ja) * | 2001-07-16 | 2004-07-22 | エフ.ホフマン−ラ ロシュ アーゲー | Ep4受容体作用薬としてのプロスタグランジン類似体 |
PT1417975E (pt) * | 2001-07-23 | 2011-05-30 | Ono Pharmaceutical Co | Medicamentos que cont?m um agonista de ep4 como princ?pio activo destinados a doen?as associadas a perda de massa ?ssea |
ES2360604T3 (es) * | 2001-07-23 | 2011-06-07 | Ono Pharmaceutical Co., Ltd. | Remedios para enfermedades con pérdida de masa osea que tienen como ingrediente activo agonistas de ep4. |
WO2003041717A1 (fr) * | 2001-11-12 | 2003-05-22 | Ono Pharmaceutical Co., Ltd. | Preparation pelliculaire persistante pour administration localisee contenant un derive de prostaglandine |
WO2003047417A2 (en) * | 2001-12-03 | 2003-06-12 | Merck & Co., Inc. | Ep4 receptor agonist, compositions and methods thereof |
US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
CA2469075C (en) | 2001-12-20 | 2011-09-13 | Applied Research Systems Ars Holding N.V. | Pyrrolidine derivatives as prostaglandin modulators |
IL163866A0 (en) | 2002-03-05 | 2005-12-18 | Ono Pharmaceutical Co | 8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredient |
AU2003209571A1 (en) * | 2002-03-18 | 2003-09-29 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
AU2011202937B2 (en) * | 2002-05-14 | 2012-06-07 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
EP1513589B1 (de) | 2002-06-06 | 2010-11-10 | Merck Frosst Canada Ltd. | 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom |
CA2483555A1 (en) | 2002-06-10 | 2003-12-18 | Applied Research Systems Ars Holding N.V. | Gamma lactams as prostaglandin agonists and use thereof |
ES2393321T3 (es) | 2002-10-10 | 2012-12-20 | Ono Pharmaceutical Co., Ltd. | Promotores de la producción de factores de reparación endógenos |
EP1581503A4 (de) | 2002-11-08 | 2007-07-25 | Merck & Co Inc | Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie |
US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
WO2004063158A1 (en) * | 2003-01-10 | 2004-07-29 | F.Hoffmann-La Roche Ag | 2-piperidone derivatives as prostaglandin agonists |
US7256211B1 (en) | 2003-01-21 | 2007-08-14 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivatives and medical use thereof |
DE602004013559D1 (de) | 2003-03-03 | 2008-06-19 | Serono Lab | G-lactamderivate als prostaglandinagonisten |
US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
US7179820B2 (en) | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
WO2005012232A2 (en) * | 2003-07-18 | 2005-02-10 | Applied Research Systems Ars Holding N.V. | Hydrazide derivatives as prostaglandin receptors modulators |
JP2007504228A (ja) | 2003-09-02 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼組成物 |
JP4546961B2 (ja) | 2003-09-04 | 2010-09-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 高眼圧の治療のための眼科用組成物 |
CA2537430A1 (en) | 2003-09-04 | 2005-03-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
CA2574078A1 (en) | 2004-07-20 | 2006-02-23 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
AU2005313380A1 (en) | 2004-12-06 | 2006-06-15 | Merck Serono Sa | Pyrrolidin-2-one derivatives for use as DP1 receptor agonists |
US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
US20090074844A1 (en) | 2005-04-28 | 2009-03-19 | Ono Pharmaceutical Co., Ltd. | Trenadermal absorption preparation |
KR100686186B1 (ko) * | 2005-06-13 | 2007-02-26 | 영진종합건설 주식회사 | 교량용 배수 구조물 |
WO2007017687A2 (en) | 2005-08-09 | 2007-02-15 | Asterand Uk Limited | Ep2 receptor agonists |
EP2085088A4 (de) | 2006-10-26 | 2012-08-29 | Ono Pharmaceutical Co | Klebende zubereitung |
WO2008073748A1 (en) | 2006-12-08 | 2008-06-19 | University Of Rochester | Expansion of hematopoietic stem cells |
EP2220057A4 (de) | 2007-11-14 | 2011-10-12 | Cayman Chem Co | Prostaglandin-e1- und e2-analoga zur behandlung verschiedener medizinischer leiden |
CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
US9682065B2 (en) | 2011-08-02 | 2017-06-20 | Ono Pharmaceutical Co., Ltd. | Left ventricular diastolic function improving agent |
CN106748951B (zh) | 2012-07-19 | 2020-07-24 | 开曼化学股份有限公司 | 作为在治疗ep4介导的疾病和病状中使用的ep4受体选择性激动剂的二氟内酰胺化合物 |
WO2014069401A1 (ja) | 2012-10-29 | 2014-05-08 | 株式会社カルディオ | 肺疾患特異的治療剤 |
US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
US9688627B2 (en) * | 2013-03-15 | 2017-06-27 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
KR20160048054A (ko) | 2013-07-19 | 2016-05-03 | 카이맨 케미칼 컴파니 인코포레이티드 | 골 성장의 촉진을 위한 방법, 시스템 및 조성물 |
KR20220147691A (ko) | 2013-08-09 | 2022-11-03 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
WO2016199111A1 (en) | 2015-06-12 | 2016-12-15 | Simon Fraser University | Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof |
JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス, インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR897566A (fr) | 1942-08-28 | 1945-03-26 | Bopp & Reuther Gmbh | Machine à rotors |
US3528961A (en) | 1966-08-16 | 1970-09-15 | Allied Chem | Monoazo dyes from e-caprolactam |
US3780095A (en) | 1970-04-08 | 1973-12-18 | Byk Gulden Lomberg Chem Fab | Acylated anilino-carboxylic acids and their salts |
US3987091A (en) | 1973-04-12 | 1976-10-19 | Merck & Co., Inc. | 11,12-secoprostaglandins |
US4033996A (en) | 1973-04-25 | 1977-07-05 | Merck & Co., Inc. | 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins |
SE7414770L (de) | 1973-12-13 | 1975-06-16 | Merck & Co Inc | |
DK366475A (da) | 1974-08-30 | 1976-03-01 | Merck & Co Inc | Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner |
US3991106A (en) | 1974-09-13 | 1976-11-09 | Merck & Co., Inc. | 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins |
US4055596A (en) | 1974-09-13 | 1977-10-25 | Merck & Co., Inc. | 11,12-Seco-prostaglandins |
US4113873A (en) | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
US4175203A (en) | 1976-12-17 | 1979-11-20 | Merck & Co., Inc. | Interphenylene 11,12-secoprostaglandins |
US4243678A (en) | 1977-12-30 | 1981-01-06 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Acylhydrocarbylaminoalkanoic acids, compositions and uses |
DE3000377A1 (de) | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
DE3042482A1 (de) | 1980-11-11 | 1982-06-24 | A. Nattermann & Cie GmbH, 5000 Köln | N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
EP0068968B1 (de) | 1981-06-16 | 1985-09-18 | Choay S.A. | Arzneimittel als wirksame Substanzverbindungen die den Arylbenzensulfonamid-Typ enthalten und Verfahren zu deren Herstellung |
AU6427596A (en) * | 1992-04-14 | 1996-10-31 | Alfred Maximillian Stessl | A boat hull |
TW383306B (en) | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
PT951282E (pt) * | 1996-12-20 | 2008-06-09 | Pfizer | Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2 |
GB2330307A (en) * | 1998-02-07 | 1999-04-21 | Glaxo Group Ltd | EP4 Receptor antagonists as bone resorption inhibitors |
CA2346038A1 (en) * | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
AU6427599A (en) * | 1998-10-15 | 2000-05-01 | Merck & Co., Inc. | Methods for stimulating bone formation |
-
2000
- 2000-11-20 CZ CZ20022048A patent/CZ20022048A3/cs unknown
- 2000-11-20 WO PCT/IB2000/001711 patent/WO2001046140A1/en active Application Filing
- 2000-11-20 AP APAP/P/2001/002357A patent/AP2001002357A0/en unknown
- 2000-11-20 OA OA1200200177A patent/OA12117A/en unknown
- 2000-11-20 SK SK855-2002A patent/SK8552002A3/sk unknown
- 2000-11-20 UA UA2002065186A patent/UA72293C2/uk unknown
- 2000-11-20 GE GEAP20006502A patent/GEP20043203B/en unknown
- 2000-11-20 EA EA200200505A patent/EA005293B1/ru not_active IP Right Cessation
- 2000-11-20 AP APAP/P/2002/002555A patent/AP2002002555A0/en unknown
- 2000-11-20 AU AU12931/01A patent/AU1293101A/en not_active Abandoned
- 2000-11-20 BR BR0016560-3A patent/BR0016560A/pt not_active IP Right Cessation
- 2000-11-20 PL PL00356662A patent/PL356662A1/xx not_active Application Discontinuation
- 2000-11-20 CN CN00817566A patent/CN1413190A/zh active Pending
- 2000-11-20 EE EEP200200355A patent/EE200200355A/xx unknown
- 2000-11-20 TR TR2002/01643T patent/TR200201643T2/xx unknown
- 2000-11-20 MX MXPA02006322A patent/MXPA02006322A/es active IP Right Grant
- 2000-12-11 TR TR2003/01841T patent/TR200301841T4/xx unknown
- 2000-12-11 EP EP00311034A patent/EP1110949B1/de not_active Expired - Lifetime
- 2000-12-11 DK DK00311034T patent/DK1110949T3/da active
- 2000-12-11 DE DE60005471T patent/DE60005471T2/de not_active Expired - Fee Related
- 2000-12-11 AT AT00311034T patent/ATE250575T1/de not_active IP Right Cessation
- 2000-12-11 PT PT00311034T patent/PT1110949E/pt unknown
- 2000-12-11 ES ES00311034T patent/ES2204458T3/es not_active Expired - Lifetime
- 2000-12-14 IL IL14032500A patent/IL140325A0/xx unknown
- 2000-12-15 US US09/738,670 patent/US6737437B2/en not_active Expired - Fee Related
- 2000-12-19 KR KR10-2000-0078214A patent/KR100419681B1/ko not_active IP Right Cessation
- 2000-12-19 PE PE2000001368A patent/PE20010953A1/es not_active Application Discontinuation
- 2000-12-20 AU AU72393/00A patent/AU763983B2/en not_active Ceased
- 2000-12-20 ZA ZA200007694A patent/ZA200007694B/xx unknown
- 2000-12-20 CA CA002329678A patent/CA2329678A1/en not_active Abandoned
- 2000-12-21 HU HU0005001A patent/HUP0005001A3/hu unknown
- 2000-12-22 CO CO00097391A patent/CO5251453A1/es not_active Application Discontinuation
- 2000-12-22 JP JP2000390594A patent/JP2001181210A/ja not_active Ceased
-
2001
- 2001-11-16 US US09/991,585 patent/US6642266B2/en not_active Expired - Fee Related
-
2002
- 2002-05-17 IS IS6388A patent/IS6388A/is unknown
- 2002-06-12 CR CR6678A patent/CR6678A/es not_active Application Discontinuation
- 2002-06-13 MA MA26686A patent/MA26852A1/fr unknown
- 2002-06-18 NO NO20022925A patent/NO20022925D0/no not_active Application Discontinuation
- 2002-06-20 HR HRP20020537 patent/HRP20020537A2/hr not_active Application Discontinuation
- 2002-06-28 BG BG106882A patent/BG106882A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE250575T1 (de) | Ep4 rezeptor selektive agonisten zur behandlung der osteoporose | |
NO20032360D0 (no) | EP4 reseptor selektive agonister for behandling av osteoporose | |
DE60032905D1 (de) | Selektive iglur5 rezeptorantagonisten zur behandlung der migräne | |
DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
DE69928542D1 (de) | 5ht2-agoniste zur behandlung des glaukoms | |
DE60138129D1 (de) | Apparat zur behandlung von zähnen | |
ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
ATE417602T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
NO20034122D0 (no) | Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte | |
NO20022105D0 (no) | Positive modulatorer av nikotinreseptoragonister | |
DE60019158D1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
DE10082139T1 (de) | Zusammensetzung zur Behandlung von Reibungspaaren | |
DE69819515D1 (de) | Hydroxy-prostaglandinderivaten zur behandlung der erektilen dysfunktion | |
ATE370728T1 (de) | Antagonisten des gardos-kanals | |
DE60031790D1 (de) | Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen | |
ATE358483T1 (de) | Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen | |
DE60012554D1 (de) | Beta-agonisten zur behandlung der endometriose bzw. unfruchtbarkeit oder steigerung der fruchtbarkeit | |
NO20022142L (no) | Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon | |
FI5227U1 (fi) | Laitteisto laastin jakelemiseksi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |